Тромболитическая терапия при ишемическоминсульте
Тромболитическая терапия при ишемическоминсульте
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. См. на сайте: http://www.eso-stroke.org
2. del Zoppo GJ, Saver JL, Jauch EC, Adams HP. Jr and on behalf of the American Heart Association Stroke Council. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator. A Science Advisory From the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945.
3. Tissue Plasminogen Activator For Acute Ishemic Stroke. The New Engl J Med 1995; 333 (24).
4. Hacke W, Kaste M, Fieschi C et al., for the ECASS Study Group. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274 (13).
5. Hacke W, Kaste M, Fieschi C et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136): 1245–51.
6. Clark WM, Wissman S, Albers GW et al., for the ATLANTIS Study Investigators. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999; 282: 2019–26.
7. The ATLANTIS, ECASS, AND NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768–74.
8. Hacke W, Kaste M, Bluhmki E et al., for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4,5 Hours after Acute Ischemic S troke. N Engl J Med 2008; 359: 131–729.
9. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial – Italy (Mast-I) Group. Lancet 1995; 346 (8989): 1509–14.
10. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicentre Acute Stroke Trial – Europe Study Group. N Engl J Med 1996; 335 (3): 145–50.
11. Yasaka M, Chambers BR, Davis SM, Donnan GA. Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group. Neurology 1998; 50 (3): 626–32.
12. Furlan AJ, Eyding D, Albers GW et al., for the DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset. Stroke 2006; 37: 1227–31.
13. Hacke W, Albers G, Yasir Al-Rawi et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). A Phase II MRI – Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase. Stroke 2005; 36: 66–73.
14. Lancet Neurol 2009; 8 (2): 141–50.
15. www.controlled-trials.com.
16. del Zoppo GJ, Higashida RT, Furlan AJ et al. PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke. Stroke 1998; 29: 4–11.
17. Lewandowski CA, Frankel M, Tomsick TA et al. Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30: 2598–605.
18. Combined Intravenous and Intra-arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study. The IMS Study Investigators. Stroke 2004; 35: 904–12.
19. The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38: 2127–35.
20. www.ims3.org.
21. Lisboa RC, Jovanovic BD, Alberts MJ. Analysis of the Safety and Efficacy of Intra-Arterial Thrombolytic Therapy in Ischemic Stroke. Stroke 2002; 33: 2866–71.
22. Скворцова В.И., Голухов Г.Н., Губский Л.В. и др. Системная тромболитическая терапия при ишемическом инсульте. Журн. неврол. и психиатр. им. С.С.Корсакова. 2006; 106 (12): 24–31.
23. Скворцова В.И., Голухов Г.Н., Волынский Ю.Д. и др. Высокая эффективность селективного внутриартериального тромболизиса при лечении ишемического инсульта у больных с окклюзией артерий крупного калибра. Журн. неврол. и психиатр. им. С.С.Корсакова. 2006; 106 (12): 32–40.
2. del Zoppo GJ, Saver JL, Jauch EC, Adams HP. Jr and on behalf of the American Heart Association Stroke Council. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator. A Science Advisory From the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945.
3. Tissue Plasminogen Activator For Acute Ishemic Stroke. The New Engl J Med 1995; 333 (24).
4. Hacke W, Kaste M, Fieschi C et al., for the ECASS Study Group. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274 (13).
5. Hacke W, Kaste M, Fieschi C et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136): 1245–51.
6. Clark WM, Wissman S, Albers GW et al., for the ATLANTIS Study Investigators. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999; 282: 2019–26.
7. The ATLANTIS, ECASS, AND NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768–74.
8. Hacke W, Kaste M, Bluhmki E et al., for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4,5 Hours after Acute Ischemic S troke. N Engl J Med 2008; 359: 131–729.
9. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial – Italy (Mast-I) Group. Lancet 1995; 346 (8989): 1509–14.
10. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicentre Acute Stroke Trial – Europe Study Group. N Engl J Med 1996; 335 (3): 145–50.
11. Yasaka M, Chambers BR, Davis SM, Donnan GA. Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group. Neurology 1998; 50 (3): 626–32.
12. Furlan AJ, Eyding D, Albers GW et al., for the DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset. Stroke 2006; 37: 1227–31.
13. Hacke W, Albers G, Yasir Al-Rawi et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). A Phase II MRI – Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase. Stroke 2005; 36: 66–73.
14. Lancet Neurol 2009; 8 (2): 141–50.
15. www.controlled-trials.com.
16. del Zoppo GJ, Higashida RT, Furlan AJ et al. PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke. Stroke 1998; 29: 4–11.
17. Lewandowski CA, Frankel M, Tomsick TA et al. Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30: 2598–605.
18. Combined Intravenous and Intra-arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study. The IMS Study Investigators. Stroke 2004; 35: 904–12.
19. The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38: 2127–35.
20. www.ims3.org.
21. Lisboa RC, Jovanovic BD, Alberts MJ. Analysis of the Safety and Efficacy of Intra-Arterial Thrombolytic Therapy in Ischemic Stroke. Stroke 2002; 33: 2866–71.
22. Скворцова В.И., Голухов Г.Н., Губский Л.В. и др. Системная тромболитическая терапия при ишемическом инсульте. Журн. неврол. и психиатр. им. С.С.Корсакова. 2006; 106 (12): 24–31.
23. Скворцова В.И., Голухов Г.Н., Волынский Ю.Д. и др. Высокая эффективность селективного внутриартериального тромболизиса при лечении ишемического инсульта у больных с окклюзией артерий крупного калибра. Журн. неврол. и психиатр. им. С.С.Корсакова. 2006; 106 (12): 32–40.
Авторы
В.И.Скворцова, Н.А.Шамалов
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.